3-methylpyridine-2-carbonitrile | CAS:20970-75-6

We serve 3-methylpyridine-2-carbonitrile CAS:20970-75-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-methylpyridine-2-carbonitrile

Chemical Name:3-methylpyridine-2-carbonitrile
CAS.NO:20970-75-6
Synonyms:3-methylpyridine-2-carbonitrile
2-cyano-3-methylpyridine
3-Methylpicolinonitrile
3-Methyl-2-pyridinecarbonitrile
3-methyl-2-cyanopyridine
Molecular Formula:C7H6N2
Molecular Weight:118.13600
 
Physical and Chemical Properties:
Density:1.08
Melting point:83-87ºC
Boiling point:141ºC
Flash point:115ºC
Index of Refraction:1.531
 
Specification:
Appearance:Light yellow crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 3-methylpyridine-2-carbonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-methyl-2-cyanopyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-methyl-2-cyanopyridine Use and application,2-cyano-3-methylpyridine technical grade,usp/ep/jp grade.


Related News: Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.2,6-Difluorobenzaldehyde manufacturer Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.2-(7-Methoxynaphthalen-1-yl)Acetic Acid supplier Beta Bionics is pursuing regulatory approval of its insulin-only bionic pancreas, followed by its dual-hormone system, which will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydrates. Beta Bionics operates in Massachusetts and California.dipropyl disulfide vendor In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum.In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum.